相关实验视频

Updated: Jul 26, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

对奥西默提尼布的罕见抗性变化进行反击-应对

Matthew G Krebs¹, Sanjay Popat²

¹Division of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, United Kingdom.

Clinical cancer research : an official journal of the American Association for Cancer Research

|June 14, 2023

概括

罕见的RET融合可以导致EGFR突变肺癌对奥西默提尼布的耐药性. 结合RET和osimertinib抑制剂显示出希望,但在这些难以治疗的病例中,需要新的策略才能获得监管部门的批准.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

经EGFR突变的非小细胞肺癌 (NSCLC) 通常会对奥西默提尼布产生耐药性.
在NSCLC中,RET融合代表了一种罕见但显著的获得性耐异性对奥西默蒂尼布的机制.
识别和克服抵抗机制对于改善患者的治疗结果至关重要.

研究的目的:

突出 RET 融合在 EGFR 突变的 NSCLC 中 osimertinib 耐药性的作用.
讨论联合RET和 osimertinib抑制的临床潜力.
强调需要创新的方法,在罕见的电阻设置中获得监管批准.

主要方法:

审查现有的临床数据和文学关于 osimertinib 耐药性的评论.
在临床前和临床研究中分析RET抑制剂的疗效.
讨论药物开发中的挑战和罕见症候群的监管途径.

主要成果:

RET融合是对 osimertinib 获得耐药性的新兴原因.
同时抑制RET和osimertinib显示出有前途的临床活性.
目前的治疗策略在获得罕见抗性突变的监管批准方面面临挑战.

结论:

准RET融合是克服NSCLC中osimertinib耐药性的可行策略.
需要进一步的研究和创新的监管策略,才能将这些疗法带给患者.
解决罕见的抗药性机制对于推进精确瘤学的发展至关重要.

更多相关视频

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...